Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #43 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 435,863 | 146.5 | 13.7% | 11.0% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 246,660 | 83.9 | 15.3% | 62.7% | 0.32% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 162,454 | 78.2 | 12.2% | 34.6% | 0.79% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 115,910 | 33.3 | 17.3% | 17.2% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 108,736 | 35.4 | 11.2% | -11.0% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,969 | 122.5 | 17.1% | 127.1% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 103,406 | 47.4 | 11.7% | 2.6% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 102,916 | 154.7 | 10.9% | -0.9% | — | 62 | 33 | 71 |
| Strides Pharma Science Limited (this stock) | 10,323 | 42.5 | 18.2% | 36.7% | 0.45% | 60 | 51 | 49 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 1,265 | 201 | 165 | ₹ |
| March 31, 2026 | 1,323 | 147 | 129 | ₹ |
| Dec. 31, 2025 | 1,195 | 246 | 208 | ₹ |
| Sept. 30, 2025 | 1,221 | 154 | 132 | ₹ |
| June 30, 2025 | 1,120 | 122 | 106 | ₹ |
| March 31, 2025 | 1,190 | 103 | 86 | ₹ |
| Dec. 31, 2024 | 1,154 | 113 | 90 | ₹ |
| Sept. 30, 2024 | 1,201 | 128 | 94 | ₹ |
| June 30, 2024 | 1,088 | 97 | 68 | ₹ |
| March 31, 2024 | 1,084 | 78 | 10 | ₹ |
| Dec. 31, 2023 | 1,038 | 62 | 54 | ₹ |
| Sept. 30, 2023 | 999 | -115 | -149 | ₹ |
| June 30, 2023 | 930 | 33 | -9 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 4,859 | 668 | 575 |
| March 31, 2025 | 4,565 | 485 | 3,598 |
| March 31, 2024 | 4,051 | 59 | -94 |
| March 31, 2023 | 3,688 | -1 | -212 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 703 | -173 | -453 | 423 | 280 |
| March 31, 2025 | 684 | -90 | -643 | 242 | 442 |
| March 31, 2024 | 701 | -150 | -693 | 118 | 583 |
| March 31, 2023 | 44 | 302 | -214 | 95 | -51 |
| March 31, 2022 | -258 | -119 | 421 | 143 | -401 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 6,927 | 3,149 | 3,015 | 1,116 | 552 | 3,613 | 2,895 | 189 | 992 | 1,635 |
| March 31, 2025 | 6,049 | 2,586 | 2,460 | 1,224 | 571 | 3,099 | 2,592 | 113 | 881 | 1,278 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
